CLINICIAN TESTIMONIALS
Patient Case: “Test results changed my treatment plan to focus on agents sensitive to crossing the blood-brain barrier.”
Dr. Eboni Cornish’s Patient Case
I treated this patient for about 6 months. And we were ascertaining some gains but not enough. So my questions was do I need to switch my management to more of central nervous system penetration, agents that really target the CNS. I chose this Panel because I felt that was the way to get that answer.
WATCH VIDEO: DR. CORNISH’S PATIENT CASE
Dr. Eboni Cornish:
One patient that comes to mind is a young woman. She was diagnosed with PANDAS, positive serology. She also had PANS with Borrelia burgdorferi positive, Bartonella henselae, seropositive and mycoplasma pneumoniae.
She presented with very severe neuropsychiatric symptoms.
I treated this patient for about 6 months. And we were ascertaining some gains but not enough. So my questions was do I need to switch my management to more of central nervous system penetration, agents that really target the CNS.
I chose this Panel because I felt that was the way to get that answer.
SPECT scan imaging is one of the things we use often at Amen Clinics. And when I see a toxic or inflammatory brain scan, that’s when I know I need to do my due diligence.
For this patient ─ Yes, she had a toxic inflammatory brain scan but on that differential diagnosis, even after this length of treatment, is there still active neurologic infection?
The Cunningham Panel was able to show me that. It was the only test. When I looked at the CaMKII, which was extremely high, despite being on numerous antimicrobial interventions, it made me get a better understanding of why she is still suffering. That infection had not resolved.
It [the Cunningham Panel] allowed for me to take a step back to change my management for that patient. To then utilize in my protocol, more agents that were sensitive to crossing the blood-brain barrier.
And to give that mom the reassurance that yes, we do need to treat the infection. Yes, this infection is active. So, let’s just focus on agents that penetrate that blood-brain barrier.
And she’s back at school now, she was homebound, once we changed her management. But I wouldn’t have had that confirmation had I not had those antibody studies for her.
It was like taking a more aggressive approach and kind of shifting how I was treating this patient because it [Cunningham Panel] showed me that the underlying infection was not in remission, as of yet.
LEARN MORE: AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS
PANS/PANDAS Overview
PANDAS & PANS Patient Stories
